Search
01/01/2026
Adverse events associated with the use of flumazenil in the Emergency Department
Ramos, JR, Peláez, MG, Clemente, YC, Requejo, CC, Alcón, EV, Mora, JRR, Blanch, CT, Palomares, AG, Costas, DG. Adverse events associated with the use of flumazenil in the Emergency Department. MEDICINA CLINICA. 2026; 166(1)DOI:10.1016/j.medcli.2025.107312. PMID:41534387. IF:2.100(Q2/3D).
31/12/2025
Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
Calle, C, Elez, E, Manzano, JL, Moreno-Martinez, ME, Pericay, C, Graefenhain, R, Ariznavarreta, A, Lizan, L. Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis. Journal Of Pharmaceutical Policy And Practice. 2025; 18(1)DOI:10.1080/20523211.2025.2567970. PMID:41415036. IF:(Q/D).
01/01/2024
Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.
Vilarrasa E, Nicolau J, de la Cueva P, Goday A, Gallardo F, Martorell A, Carrascosa JM. Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.. Actas Dermo-Sifiliograficas. 2024; 115(1)DOI:10.1016/j.ad.2023.06.017. PMID:37451337. IF:(Q/D).
01/01/2024
Therapeutic outcomes and survival analysis of Extramammary Paget's disease: A multicentre retrospective study of 249 patients.
Escolà H, Llombart B, Escolà-Rodríguez A, Barchino-Ortiz L, Marcoval J, Alcaraz I, Beà-Ardébol S, Toll A, Miñano-Medrano R, Rodríguez-Jiménez P, López-Nuñez M, Ferrándiz-Pulido C, Jaka A, Masferrer E, Aguayo-Ortiz RS, Yébenes M, Arandes-Marcocci J, Ruiz-Salas V, Turrión-Merino L, Just M, Sánchez-Schmidt J, Leal L, Mayo-Martínez F, Haya-Martínez L, Sandoval-Clavijo A, Dradi GG, Delgado Y, Verdaguer-Faja J, López-Castillo D, Pujol RM, Deza G. Therapeutic outcomes and survival analysis of Extramammary Paget's disease: A multicentre retrospective study of 249 patients.. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2024; 90(1)DOI:10.1016/j.jaad.2023.08.088. PMID:37704106. IF:11.800(Q1/1D).
01/12/2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espaillat R, Sinvhal R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(6)DOI:10.1016/j.jaad.2023.07.1024. PMID:37553030. IF:12.800(Q1/1D).
01/12/2023
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.
Egeberg A, Kristensen LE, Puig L, Rich P, Smith SD, Garrelts A, See K, Holzkaemper T, Fotiou K, Schuster C. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.. JOURNAL OF DERMATOLOGICAL TREATMENT. 2023; 34(1)DOI:10.1080/09546634.2023.2263108. PMID:37781881. IF:2.900(Q2/4D).